Posted inNews and Updates
Sound Pharmaceuticals Completes SPI-1005 Clinical Trial
Sound Pharmaceuticals has wrapped up enrollment for its Phase 3 SPI-1005 trial, targeting new treatments for sensorineural hearing loss and Meniere’s disease.
Posted inNews and Updates
New ALS Drug Shows Promise in Phase 1 Clinical Trial
Researchers report promising safety and biomarker results in a Phase 1 trial for a new siRNA-based treatment targeting SOD1-associated ALS.
Posted inNews and Updates
Vietnam Pharma Market to Hit $10B: Growth Drivers Revealed
Vietnam’s pharma sector is set to exceed $10B as aging demographics and new regulatory reforms spark rapid growth in the regional healthcare market.
Posted inNews and Updates
Why Nearly 60% of Clinical Trial Sites Fail to Retain Patients
Over half of all clinical trial sites struggle with patient loss due to inefficiencies. Discover the operational fixes needed to boost retention and R&D.
Posted inNews and Updates
ORIC Launches Phase 3 Trial of Rinzimetostat for mCRPC
ORIC Pharmaceuticals has launched the Phase 3 Himalayas-1 trial, testing rinzimetostat as a targeted treatment for metastatic castration-resistant prostate cancer.
Posted inNews and Updates
Lung Cancer Breakthrough: Sac-TMT Shows Promise in NSCLC
New clinical trial data shows the combination of sac-TMT and pembrolizumab hits primary endpoints for patients with PD-L1-negative NSCLC. Read more here.
Posted inNews and Updates
Digital Twins: How Simulation is Transforming Drug Research
Discover how clinical trial simulation and digital twins are slashing R&D costs and accelerating drug development by replacing traditional research models.
Posted inNews and Updates
FDA Grants Priority Review for Gazyva in Kidney Disease
The FDA has granted Priority Review to Gazyva for Primary Membranous Nephropathy. Explore how this CD20-directed therapy could transform kidney care.
Posted inNews and Updates
Zemprocitinib Phase III Trial: New Hope for Ankylosing Spondylitis
Lynk Pharmaceuticals completes enrollment for its Phase III trial of Zemprocitinib, a promising new JAK inhibitor for treating Ankylosing Spondylitis.
Posted inNews and Updates
Veradermics Reveals Phase 2 Data for Hair Loss Drug VDPHL01
Veradermics announces Phase 2 results for VDPHL01, a potential new treatment for mild-to-moderate female pattern hair loss. Get the latest clinical trial data.